Nebenwirkungen · Riltrava Aerosphere
Riltrava Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension · Abschnitt 4.8 · PDF-Seite 9
HOS-146200 · Präparat HOS-099464
Pneumonia KRONOS was a 24-week study in a total of 1,896 patients with moderate to very severe COPD (mean post-bronchodilator screening FEV1 50% of predicted, standard deviation [SD] 14%), 26% of whom had experienced a COPD exacerbation in the year prior to study entry. The incidence of confirmed pneumonia events reported up to 24 weeks was 1.9% (12 patients) for Riltrava Aerosphere (n=639), 1.6% (10 patients) for formoterol fumarate dihydrate/glycopyrronium (FOR/GLY) MDI 5/7.2 micrograms (n=625), 1.9% (6 patients) for formoterol fumarate dihydrate/budesonide (FOR/BUD) MDI 5/160 micrograms (n=314) and 1.3% (4 patients) for open-labelled formoterol fumarate dihydrate/budesonide Turbuhaler (FOR/BUD) TBH 6/200 micrograms (n=318).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T16:35:00Z · SHA-256 2c3c1f837c02fb01a9b23f0bee262799934d841507f0e523790d6c8028b6fe72 · Passage 85f3ae1914d1db4265d1fc3a89fbdd12fd51dd3f0cfaf12ac2479846b5c04018 · Zeichen 4081–4817 im Abschnitt